{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T00:28:46Z","timestamp":1762043326723,"version":"build-2065373602"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jns.2021.120083","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T00:03:34Z","timestamp":1639181014000},"page":"120083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Characteristics of wearing-off and motor symptoms improved by safinamide adjunct therapy in patients with Parkinson's disease: A post hoc analysis of a Japanese phase 2\/3 study"],"prefix":"10.1016","volume":"434","author":[{"given":"Masahiro","family":"Nomoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michinori","family":"Koebis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ippei","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobutaka","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2021.120083_bb0005","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson\u2019s disease, 1990-2016: a systematic analysis for the global burden of disease study 2016","volume":"17","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2021.120083_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","article-title":"Parkinson disease epidemiology, pathology, genetics, and pathophysiology","volume":"36","author":"Simon","year":"2020","journal-title":"Clin. Geriatr. Med."},{"key":"10.1016\/j.jns.2021.120083_bb0015","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1093\/brain\/awp234","article-title":"A clinico-pathological study of subtypes in Parkinson\u2019s disease","volume":"132","author":"Selikhova","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.jns.2021.120083_bb0020","doi-asserted-by":"crossref","DOI":"10.2174\/1871527319666200722153156","article-title":"Levodopa therapy for Parkinson\u2019s disease: history, current status and perspectives","author":"Bogetofte","year":"2020","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.jns.2021.120083_bb0025","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/mds.26712","article-title":"Unmasking levodopa resistance in Parkinson\u2019s disease","volume":"31","author":"Nonnekes","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2021.120083_bb0030","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s40263-020-00754-0","article-title":"Non-dopaminergic treatments for motor control in Parkinson\u2019s disease: an update","volume":"34","author":"Gonzalez-Latapi","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jns.2021.120083_bb0035","doi-asserted-by":"crossref","DOI":"10.1007\/s13311-020-00889-4","article-title":"Medical management and prevention of motor complications in Parkinson\u2019s disease","author":"Aradi","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jns.2021.120083_bb0040","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jns.2021.120083_bb0045","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1124\/jpet.117.245100","article-title":"Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia","volume":"364","author":"Morari","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jns.2021.120083_bb0050","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0022-3565(24)38068-1","article-title":"Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound","volume":"288","author":"Salvati","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jns.2021.120083_bb0055","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mds.25751","article-title":"Randomized trial of safinamide add-on to levodopa in Parkinson\u2019s disease with motor fluctuations","volume":"29","author":"Borgohain","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2021.120083_bb0060","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/mds.25961","article-title":"Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson\u2019s disease","volume":"29","author":"Borgohain","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2021.120083_bb0065","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamaneurol.2016.4467","article-title":"Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial","volume":"74","author":"Schapira","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jns.2021.120083_bb0070","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2020.04.012","article-title":"Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled, phase II\/III study","volume":"75","author":"Hattori","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2021.120083_bb0075","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/dtb.2018.5.0623","volume":"56","author":"Safinamide for Parkinson\u2019\u2019s disease","year":"2018","journal-title":"Drug Ther. Bull."},{"key":"10.1016\/j.jns.2021.120083_bb0080","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1254\/fpj.20012","article-title":"Safinamide Mesilate (Equfina\u00ae tablets 50 mg): preclinical and clinical pharmacodynamics, efficacy, and safety","volume":"155","author":"Koebisu","year":"2020","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"10.1016\/j.jns.2021.120083_bb0085","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3233\/JPD-150700","article-title":"Safinamide as add-on therapy to levodopa in mid- to late-stage Parkinson\u2019s disease fluctuating patients: Post hoc analyses of studies 016 and SETTLE","volume":"6","author":"Cattaneo","year":"2016","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.jns.2021.120083_bb0090","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3233\/JPD-191765","article-title":"Long-term efficacy of safinamide on symptoms severity and quality of life in fluctuating Parkinson\u2019s disease patients","volume":"10","author":"Cattaneo","year":"2020","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.jns.2021.120083_bb0095","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.parkreldis.2014.02.024","article-title":"Symptomatic efficacy of rasagiline monotherapy in early Parkinson\u2019s disease: post-hoc analyses from the ADAGIO trial","volume":"20","author":"Jankovic","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2021.120083_bb0100","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.apmr.2016.10.002","article-title":"Polestriding intervention improves gait and axial symptoms in mild to moderate Parkinson disease","volume":"98","author":"Krishnamurthi","year":"2017","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"10.1016\/j.jns.2021.120083_bb0105","first-page":"1529","article-title":"Parkinson study group, variable expression of Parkinson\u2019s disease: a baseline analysis of the DATATOP cohort","volume":"40","author":"Jankovic","year":"1990","journal-title":"The Parkinson Study Group, Neurology"},{"key":"10.1016\/j.jns.2021.120083_bb0110","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/mds.28095","article-title":"A pooled analysis from phase 2b and 3 studies in Japan of istradefylline in Parkinson\u2019s disease","volume":"35","author":"Hattori","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2021.120083_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2020.105960","article-title":"Relations of clinical symptoms with dopamine transporter imaging in drug-na\u00efve Parkinson\u2019s disease","volume":"196","author":"Mito","year":"2020","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.jns.2021.120083_bb0120","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/mds.23954","article-title":"And study 015 investigators, a randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson\u2019s disease patients","volume":"27","author":"Stocchi","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2021.120083_bb0125","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.baga.2013.09.001","article-title":"Glutamate in Parkinson\u2019s disease: role of antiglutamatergic drugs","volume":"3","author":"Carrillo-Mora","year":"2013","journal-title":"Basal Ganglia"},{"key":"10.1016\/j.jns.2021.120083_bb0130","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/S1474-4422(10)70212-X","article-title":"Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson\u2019s disease","volume":"9","author":"Kehagia","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2021.120083_bb0135","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jocn.2021.05.056","article-title":"The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson\u2019s disease: clinical cases and a review of the literature","volume":"90","author":"Pagonabarraga","year":"2021","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.jns.2021.120083_bb0140","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3233\/JPD-2011-11035","article-title":"Examination of the UPDRS bradykinesia subscale: equivalence, reliability and validity","volume":"1","author":"Buck","year":"2011","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.jns.2021.120083_bb0145","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","article-title":"Parkinson\u2019s disease: clinical features and diagnosis","volume":"79","author":"Jankovic","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2021.120083_bb0150","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.nicl.2016.01.010","article-title":"Relation of 18-F-Dopa PET with hypokinesia-rigidity, tremor and freezing in Parkinson\u2019s disease","volume":"11","author":"Pikstra","year":"2016","journal-title":"Neuroimage Clin"},{"key":"10.1016\/j.jns.2021.120083_bb0155","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3109\/00207454.2013.812085","article-title":"Rasagiline treatment effects on parkinsonian tremor","volume":"123","author":"Lew","year":"2013","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.jns.2021.120083_bb0160","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.phrs.2003.12.004","article-title":"Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity","volume":"50","author":"Marzo","year":"2004","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jns.2021.120083_bb0165","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/WNF.0000000000000233","article-title":"Determination of monoamine oxidase a and B activity in long-term treated patients with Parkinson disease","volume":"40","author":"M\u00fcller","year":"2017","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jns.2021.120083_bb0170","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pbb.2013.01.015","article-title":"Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor","volume":"105","author":"Podurgiel","year":"2013","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.jns.2021.120083_bb0175","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a003947","article-title":"Voltage-gated calcium channels","volume":"3","author":"Catterall","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.jns.2021.120083_bb0180","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s12311-011-0277-y","article-title":"T-type calcium channel as a new therapeutic target for tremor","volume":"10","author":"Miwa","year":"2011","journal-title":"Cerebellum"},{"key":"10.1016\/j.jns.2021.120083_bb0185","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1212\/WNL.67.7_suppl_2.S18","article-title":"Safinamide: from molecular targets to a new anti-Parkinson drug","volume":"67","author":"Caccia","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2021.120083_bb0190","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/mds.20397","article-title":"Long-term efficacy and safety of pramipexole in advanced Parkinson\u2019s disease: results from a European multicenter trial","volume":"20","author":"M\u00f6ller","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2021.120083_bb0195","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0022-510X(91)90283-D","article-title":"Dopa-sensitive and dopa-resistant gait parameters in Parkinson\u2019s disease","volume":"103","author":"Blin","year":"1991","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2021.120083_bb0200","first-page":"453","article-title":"Fear of falling has greater influence than other aspects of gait disorders on quality of life in patients with Parkinson\u2019s disease","volume":"30","author":"Brozova","year":"2009","journal-title":"Neuro Endocrinol Lett"},{"key":"10.1016\/j.jns.2021.120083_bb0205","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1212\/01.wnl.0000313835.33830.80","article-title":"Determinants of disability and quality of life in mild to moderate Parkinson disease","volume":"70","author":"Muslimovic","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2021.120083_bb0210","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.parkreldis.2019.07.031","article-title":"Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson\u2019s disease patients: results from the COPPADIS study cohort","volume":"66","author":"Santos Garc\u00eda","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2021.120083_bb0215","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/mds.26742","article-title":"Predicting first fall in newly diagnosed Parkinson\u2019s disease: insights from a fall-na\u00efve cohort","volume":"31","author":"Lord","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2021.120083_bb0220","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1472-8206.2009.00798.x","article-title":"Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson\u2019s disease","volume":"24","author":"Devos","year":"2010","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.jns.2021.120083_bb0225","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/mds.25669","article-title":"Neurophysiology of gait: from the spinal cord to the frontal lobe","volume":"28","author":"Takakusaki","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2021.120083_bb0230","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3389\/fneur.2017.00542","article-title":"Long-term monitoring gait analysis using a wearable device in daily lives of patients with Parkinson\u2019s disease: the efficacy of selegiline hydrochloride for gait disturbance","volume":"8","author":"Iijima","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2021.120083_bb0235","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1080\/14656566.2019.1614167","article-title":"Efficacy of istradefylline for gait disorders with freezing of gait in Parkinson\u2019s disease: a single-arm, open-label, prospective, multicenter study","volume":"20","author":"Iijima","year":"2019","journal-title":"Expert. Opin. Pharmacother."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21027854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21027854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T16:00:34Z","timestamp":1758384034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X21027854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":47,"alternative-id":["S0022510X21027854"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2021.120083","relation":{},"ISSN":["0022-510X"],"issn-type":[{"type":"print","value":"0022-510X"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics of wearing-off and motor symptoms improved by safinamide adjunct therapy in patients with Parkinson's disease: A post hoc analysis of a Japanese phase 2\/3 study","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2021.120083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120083"}}